ViraTherapeutics develops highly potent cancer-destroying (oncolytic) viruses that are effective in a broad range of different cancers.
ViraTherapeutics develops anti-cancer agents based on the oncolytic (cancer-destroying) virus VSV-GP. VSV-GP is highly effective in all cancers tested in mouse models. VSV-GP is the only oncolytic virus so far that does not induce neutralizing (virus inactivating) antibodies and therefore can be given repeatedly without loss of efficacy. Thus, VSV-GP-therapeutics have the potential to revolutionize cancer therapy.